Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia

In the phase I trial of bexobrutideg (NX-5948), a novel BTK degrader for relapsed or refractory B-cell malignancies, nearly 50 patients showed a remarkable objective response rate of 80.9% in chronic lymphocytic leukemia (CLL). With reported tolerability across various doses, patients experienced significant clinical benefits, including deepening responses over time, even with prior resistance mutations. Presented by Dr. Nirav N. Shah at the 2025 SOHO Annual Meeting, these findings highlight bexobrutideg's potential to transform CLL treatment protocols.